Verano: Analysts Expect Q3 Revenues Of $219.7 Million

Verano Holdings (CSE: VRNO) announced that they will be reporting their third quarter financials before the market opens on November 16th.

Analysts have a consensus C$40.38 12-month price target on the company, via a total of 7 analysts, with 2 analysts having strong buy ratings, and the other 5 having buy ratings on the company. The street high comes from Beacon Securities with a C$47 price target, and the lowest target sits at C$35.

7 analysts have revenue estimates for the third quarter. The mean between all 7 is US$219.70 million; this number has been revised slightly down from US$224.82 million at the start of May. The street high is US$224.60 million while the lowest sits at US$210 million.

7 analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 55.41%, with this number revised down from 60.72% at the start of May. Street high is a 58% estimate and the lowest sits at 53%.

Onto EBITDA estimates, there are currently 7 analysts who have third-quarter EBITDA estimates. The mean is currently US$85.64 million, with this number being revised down from US$100.17 million since the start of May. Street high sits at US$93.50 million EBITDA and the lowest being a US$63.70 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

Total Metals Secures High Grade Critical Minerals Property In Northwestern Ontario

Discovery at Luis Hill Prompts Acceleration of Phase 2 Program for Questcorp

Related News

Antibe: Canaccord Raises Price Target After Q4 Results

On June 28th, Antibe Therapeutics (TSX: ATE) reported their fourth quarter and year-end financials. The...

Friday, July 2, 2021, 12:18:00 PM

Canaccord Drops Antibe’s Price Target To $0.70 Following Asset Sale

Antibe Therapeutics Inc. (TSX: ATE) recently reported their full-year 2022 results, wherein the company reported...

Friday, July 15, 2022, 02:25:00 PM

Mind Medicine: Canaccord Maintains Ratings Following Financial Results

On Friday, November 13th, Mind Medicine (NEO: MMED) reported their third quarter 2020 financial results....

Tuesday, November 17, 2020, 10:17:00 AM

Verano Holdings: Canaccord Reiterates $35 Price Target

On April 8th, Verano Holdings (CSE: VRNO) announced their full year 2020 and fourth quarter...

Sunday, April 11, 2021, 01:45:00 PM

Curaleaf Sees Consensus Estimates Stay Flat After Q1 Results

Curaleaf Holdings (CSE: CURA) reported its first-quarter results on May 10th, beating the consensus estimates...

Saturday, May 15, 2021, 04:24:00 PM